US20190380956A1

US20190380956A1 - Topical Composition for Pain Relief

Info

Publication number: US20190380956A1
Application number: US16/009,067
Authority: US
Inventors: Bob Fuladi
Original assignee: Individual
Current assignee: Individual
Priority date: 2018-06-14
Filing date: 2018-06-14
Publication date: 2019-12-19
Anticipated expiration: 2038-06-14
Also published as: US10517821B1; WO2019241409A1

Abstract

A topical composition for nociceptive and neuropathic pain relief comprises several of menthol, camphor, methyl sulfonyl methane, lidocaine, arnica montana, Harpagophytum tincture, Emu oil, maqui powder, turmeric oil and in some embodiments methyl salicylate or capsaicin with Cannabis sativa.

Description

BACKGROUND OF THE INVENTION

Many people suffer from pains including musculoskeletal conditions such as soft tissue trauma and arthritis. Some bear the pain associated with those conditions for prolonged periods. Treatment of musculoskeletal pain using traditional analgesics and anti-inflammatory drugs and known combinations of traditional analgesics anti-inflammatory drugs is not always effective.

FIELD OF INVENTION

This invention relates to the medicinal/chemical arts and to the treatment of nociceptive and neuropathic pain in humans.

DISCUSSION OF THE RELATED ART

Medications for the relief of pain may include analgesics and anti-inflammatories. However, compositions that include these ingredients along with local anesthetics and/or counterirritants are not well known.

SUMMARY OF THE INVENTION

The present invention provides a topical cream useful for treating nociceptive and neuropathic pain in humans.
In an embodiment, a composition includes by weight percent about 15% of counterirritant/analgesic methyl salycilate, 8% of anesthetic/analgesic, 5% of skin permeator/anti-inflammatory, 3.0% of analgesic/anti-itch/counterirritant, 2.9% of analgesic, 2.5% of analgesic/anti-inflammatory, 2.0% of anesthetic, 1.5% of antioxidant. In various embodiments, the ingredients of this composition are varied in a range of plus or minus 50%; for example, the anesthetic/analgesic is varied from 4% to 12%. In various embodiments, the ingredients of this composition are varied in a range of plus or minus 40%, in a range of plus or minus 30%, in a range of plus or minus 20%, in a range of plus or minus 10%, in a range of plus or minus 5%.
In an embodiment, a composition includes by weight percent about 8% of anesthetic/analgesic menthol, 5% of anti-inflammatory/skin permeator, 3.19% of analgesic, 3% of analgesic/anti-itch/counterirritant, 2.625% of analgesic/anti-inflammatory, 2% of anesthetic, 1.5% of antioxidant. In various embodiments, the ingredients of this composition are varied in a range of plus or minus 50%; for example, the anesthetic/analgesic ingredient is varied from 4% to 12%. In various embodiments, the ingredients of this composition are varied in a range of plus or minus 40%, in a range of plus or minus 30%, in a range of plus or minus 20%, in a range of plus or minus 10%, in a range of plus or minus 5%.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention is described with reference to the accompanying figures. These figures, incorporated herein and forming part of the specification, illustrate the present invention and, together with the description, further serve to explain the principles of the invention and to enable a person skilled in the relevant art to make and use the invention.

FIG. 1 shows an embodiment of the invention wherein methyl salicylate is a main ingredient.

FIG. 2 shows an embodiment of the invention where capsaicin and hemp oil are ingredients used in place of methyl salicylate.

FIG. 3 shows the purpose of the ingredients used in the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The disclosure provided in the following pages describes examples of some embodiments of the invention. The designs, figures, and descriptions are non-limiting examples of certain embodiments of the invention. For example, other embodiments of the disclosed device may or may not include the features described herein. Moreover, disclosed advantages and benefits may apply to only certain embodiments of the invention and should not be used to limit the disclosed inventions.
In an embodiment, the invention comprises the ingredients shown in Table 1 below.

TABLE 1

Topical Composition For Pain Relief
Ingredients In A First Embodiment

		Supplier (Lot number) +		ASA-150 gm
Item	Ingredients	other information	% W/W	batch (gm)

1	Methyl Salicylate	Spectrum	15.00	22.5
2	MSM (Methyl sulfonyl	Source Naturals (SN1535	5.00	7.5
	methane)	REVK151) used by May 2020
3	Lidocaine	Spectrum USP (IEC0028) Retest	2.00	3.0
		date Jun. 17, 2019
4	Arnica Montana (Flower	TerraVita (512592) Best	2.91	4.4
	extract) obtained from 5%	Before April 2022
	w/w of raw material
	(extracted amount along
	with propylene glycol for
	150 gm of batch (gm))
5	Ginger extract obtained	Starwest Botanical (68499)	0.50	0.8
	from 1% w/w of raw Ginger
	(extracted amount along
	with propylene glycol for
	150 gm of batch (gm))
6	Harpagophytum tincture	Bulk Supplements.com	2.50	3.8
	(Devils claw extract)
7	Menthol	Spectrum (1EE0771) Exp.	8.00	12.0
		Date: Apr. 13, 2018
8	Camphor	Spectrum (2EC0027) Exp.	3.00	4.5
		Date: Sep. 30, 2019
9	Maqui powder extract	South Life (MFDP2016-08)	1.53	2.3
	(extracted amount along	Packing date Feb. 29, 2016
	with propylene glycol for
	150 gm of batch (gm))
10	Emu Oil	PipingRock.com (6250) Exp.	0.20	0.3
		Date: not available
11	Aloe Vera	Bulk Supplements.com	1.00	1.5
		(12E0916) Best before
		Sep. 15, 2020
12	Piper nigrum (Black pepper)	Eden gardern	0.08	0.1
	oil
13	Curcuma Longa (Tumeric)	Eden gardern	0.13	0.2
	oil
14	Bergamot oil	Dr Adorable Inc, Exp. Date	0.30	0.5
		December 2018
15	Natural Saffron yellow color	Color Maker (Mfg. date	0.20	0.3
	Formula 3635C	Jun. 21, 2017)
16	Cream Base		56.66	86.49
	TOTALS		100	150

The cream base referred to in Table 1 is shown in Table 2 below.

TABLE 2

Cream Base

				ASA-
				150 gm
		Supplier (Lot number) +	%	batch
Item	Ingredients	other information	W/W	(gm)

1	Stearic acid	Spectrum NF (2FF0167)	16.00	24.0
2	Cetyl Alcohol	USB (36653-82-4)	1.00	1.5
3	Isopropyl Palmitate	Spectrum NF (2F10111)	1.00	1.5
4	Propyl Paraben	VWR USP (1GA0299)	0.15	0.2
5	Sorbitan	Spectrum NF (2FG0337)	5.00	7.5
	Monostearate
6	Methyl Paraben	VWR (3197C372)	0.10	0.2
7	Sorbitol Solution	Spectrum USP (1GC1050)	3.00	4.5
	(70%)
8	Polysorbate 60	Spectrum NF (L-15031-AP)	5.00	7.5
9	Cabopol 940	Lutriol	0.25	0.4
10	Purified water q.s.	In House	26.16	39.2
	TOTALS		56.66	86.49

Manufacturing Procedure
In a first step, weigh specified amounts of MSM, emu oil, maqui powder extract, ginger extract, arnica montana flower extract, devils claw extract, Aloe vera, methyl paraben, sorbitol solution, polysorbate 60, carbopol 940 and purified water in a suitable glass container and heat to 80±5° C. on a heated water bath and stir the mixture to disperse the mixture completely.
In a second step, weight and mix specified amounts of methyl salicylate, lidocaine, stearic acid, cetyl alcohol, isopropyl palmitate, propyl paraben, Piper nigrum (black pepper) oil, Curcuma longa (tumeric) oil, and sorbitan monostearate separately in a suitable glass container and heat to 80±5° C. on a heated water bath. Stir the dispersion to mix all components.
In a third step, mix the components of step-II with the components of step-I at 80±5° C. under continuous homogenization for 10-15 minutes.
In a fourth step, remove the mixture from the heated water bath, add specified amount of menthol, camphor, natural saffron yellow color formula 3635C and flavoring agent (bergamot mint oil) and stir continuously to disperse them uniformly.
In a fifth step, add the cream base.
In a sixth step, when the temperature of the composition is just above the solidification, the formulation is poured in to the suitable well labeled aluminum tubes. The final product is cooled down to room temperature, capped and stored at room temperature.
In an embodiment, the invention comprises the ingredients shown in Table 3 below.

TABLE 3

Topical Composition For Pain Relief
Ingredients In A Second Embodiment

				For 150 gm
		Supplier (Lot number) +		batch non-
Item	Ingredients	other information	% W/W	ASA (gm)

1	Capsaicin extract obtained from	Starwest Botanical (70519)	0.28	0.4
	0.75% raw material	Exp. Date: Jun. 20, 2019
2	MSM (Methyl sulfonyl methane)	Source Naturals (SN1535	5	7.5
		REVK151) used by May 2020
3	Lidocaine	Spectrum USP (IEC0028) Retest	2	3.0
		date Jun. 17, 2019
4	Arnica Montana (Flower extract)	TerraVita (512592) Best	2.91	4.4
	obtained from 5% w/w of raw	Before April 2022
	material (extracted amount
	along with propylene glycol for
	150 gm of batch (gm))
5	Ginger extract obtained from	Starwest Botanical (68499)	0.5	0.8
	1% w/w of raw Ginger (extracted	Exp. Date: Not available
	amount along with propylene
	glycol for 150 gm of batch (gm))
6	Harpagophytum tincture (Devils	Bulk Supplements.com	2.5	3.8
	claw extract) obtained from
	2.5% w/w of raw material*
7	Menthol	Spectrum (1EE0771) Exp.	8	12.0
		Date: Apr. 13, 2018
8	Camphor	Spectrum (2EC0027) Exp.	3	4.5
		Date: Sep. 30, 2019
9	Maqui powder extract	South Life (MFDP2016-08)	1.53	2.3
	(extracted amount along with	Packing date Feb. 29, 2016
	propylene glycol for 150 gm of
	batch (gm))
10	Emu Oil	PipingRock.com (6250) Exp.	0.2	0.3
		Date: not available
11	Aloe Vera	Bulk Supplements.com	1	1.5
		(12E0916) Best before
		Sep. 15, 2020
12	Piper nigrum (Black pepper) oil	Eden gardern	0.075	0.1
13	Curcuma Longa (Tumeric) oil	Eden gardern	0.125	0.2
14	Cannabis Sativa (Hemp) oil	Eden gardern	0.125	0.2
15	Bergamot oil	Dr Adorable Inc, Exp. Date	0.3	0.5
		December 2018
16	Natural Saffron yellow color	Color Maker (Mfg. date	0.2	0.3
	Formula 3635C	Jun. 21, 2017)
17	Cream Base		75.535	113.28
	TOTALS		100	150

The cream base referred to in Table 3 is shown in Table 2 above.
In some embodiments, the methyl salicylate listed in Table 1 is included in the list of ingredients shown in Table 3 with or without the capsaicin extract. The weight percent of this additional ingredient may be 15% with the cream base reduced by a corresponding amount. If the capsaicin extract is excluded, the cream base may be increased by a corresponding amount.
Manufacturing Procedure
In a first step, weigh specified amounts of MSM, emu oil, maqui powder extract, ginger extract, Arnica Montana Flower extract, devils claw extract, aloe vera, methyl paraben, sorbitol solution, polysorbate 60, carbopol 940 and purified water in a suitable glass container and heat to 80±5° C. on a heated water bath and stir the mixture to disperse the mixture completely.
In a second step, weight and mix specified amounts of capsaicin extract, lidocaine, stearic acid, cetyl alcohol, isopropyl palmitate, propyl paraben, Piper nigrum (black pepper) oil, Curcuma longa (tumeric) oil, Cannabis sativa (hemp) oil and sorbitan monostearate separately in a suitable glass container and heat to 80±5° C. on a heated water bath. Stir the dispersion to mix all components.
In a third step, mix the components of step-II with the components of step-I at 80±5° C. under continuous homogenization for 10-15 minutes.
In a fourth step, remove the mixture from the heated water bath, add specified amount of menthol, camphor, natural saffron yellow color formula 3635C and flavoring agent (bergamot mint oil) and homogenize continuously to disperse them uniformly.
In a fifth step, add the cream base.
In a sixth step, when the temperature of the composition is just above the solidification, the formulation is poured in to the suitable well labeled aluminum tubes. The final product is cooled down to room temperature, capped and stored at room temperature.
FIG. 1 shows the main ingredients 100 of a topical composition for pain relief used in an embodiment containing methyl salicylate. FIG. 2 shows the main ingredients 200 of a topical composition for pain relief used in an embodiment where hemp oil and capsaicin extract are used in place of methyl salicylate. FIG. 3 shows the purpose 300 of each of the topical composition for pain relief ingredients.
Experimental Results
It has been found that the composition can be used to treat generalized muscle and joint pain and inflammation. For example, the composition can be used: as a topical anti-inflammatory to treat localize inflammation; as a moisturizer and conditioner for the skin as a secondary effect when used for the purpose of reducing pain or inflammation as described above; in conjunction with other systemic anti-inflammatories as in a gouty attack, resulting in significant reduction in pain and inflammation. Localized pain relief is provided for up to 4 to 6 hours.
Recommendations for Use
Pregnancy: Use not recommended in pregnancy. Consult with your Physician prior to use.
Interactions: Consult with your Physician if on blood thinners, have kidney, liver or heart disease, and/or suffer from high blood pressure. Use only under the explicit guidance and approval of a physician if any of the above conditions exist. Allergy: Do not use this product if allergic to aspirin or to any of the active or inactive ingredients listed on the package.
Caution: Do not use with alcohol or any other topical medication. Consult a physician or a pharmacist for possible cross-reactions or interactions when taking or using other medications. Long-term use is not recommended. Chronic use beyond 7 days should be done under the supervision/guidance of a physician.
Application
For use, the composition is typically rubbed onto the skin in the areas of pain and/or inflammation, two or three times daily. Apply the cream to a small section of the affected area prior to more generalized use. Immediately stop using the cream and notify your Physician in the event of any allergic or hypersensitivity reaction. If an allergic reaction such as a rash, hives or a more severe reaction occurs, consult a medical professional immediately or call 911 should the reaction appear to be life threatening.
What follows is a random selection of exemplary results. Pain levels are recorded based on a scale of 1-3 low pain, 4-6 moderate pain, and 7-10 severe pain. Inflammation levels are recorded based on a scale of 1 for no reduction in swelling to 10 for a profound reduction in swelling. Patients 1 and 2 were treated with the first embodiment of the topical composition for pain relief. Other patients were treated with the second embodiment of the topical composition for pain relief.
Patient 1: An adult male complained of chronic back pain. A severe pain baseline of 7 was determined before use of the topical composition for pain relief. Inflammatory response was not measured. After use of the cream, a moderate pain level of 4 was determined. No adverse side effects were observed.
Patient 2: An adult male complained of a right ankle bone bruise. A moderate pain baseline of 5 was determined before use of the topical composition for pain relief. After use of the cream, a low pain level of 1 was determined along with an inflammation response of 3. No adverse side effects were observed.
Patient 3: An adult male complained of a wrist sprain. A moderate pain baseline of 6 was determined before use of the topical composition for pain relief. After use of the cream, a low pain level of 1 was determined along with an inflammation response of 3. No adverse side effects were observed.
Patient 4: An adult male complained of Achilles tendonitis. A moderate pain baseline of 5 was determined before use of the topical composition for pain relief. After 3 days of use, applying the cream twice a day, a low pain level of 1 was determined along with an inflammation response of 9. No side effects were observed.
Patient 5: An adult male complained of arthritis following knee surgery and removal of a majority of the medial meniscus. A moderate pain baseline of 4 was determined before the use of the topical composition for pain relief. After three applications of the cream over a two day period, the discomfort essentially disappeared and a pain level of 1 was determined along with an inflammation response of 5. Side effect was noticeable smell of cream during first hour after application.
While various embodiments of the present invention have been described above, it should be understood that they have been presented by way of example only, and not limitation. It will be apparent to those skilled in the art that various changes in the form and details can be made without departing from the spirit and scope of the invention. As such, the breadth and scope of the present invention should not be limited by the above-described exemplary embodiments, but should be defined only in accordance with the following claims and equivalents thereof.

Claims

What is claimed is:

1. A topical composition comprising, by weight:

10 to 20% methyl salycilate;

6 to 12% anesthetic/analgesic;

4 to 8% skin permeator/anti-inflammatory;

2 to 4% analgesic/anti-itch/counterirritant;

2 to 4% analgesic;

2 to 4% analgesic/anti-inflammatory;

1.4 to 2.6% anesthetic; and,

1 to 2% antioxidant.

2. The composition of claim 1 where the anesthetic/analgesic is menthol.

3. The composition of claim 2 where the skin permeator/anti-inflammatory is methyl sulfonyl methane.

4. The composition of claim 3 where the analgesic is Arnica montana.

5. The composition of claim 4 where the analgesic/anti-itch/counterirritant is camphor.

6. The composition of claim 5 where the analgesic/anti-inflammatory is Harpagophytim tincture.

7. The composition of claim 6 where the anesthetic is lidocaine.

8. The composition of claim 7 where the antioxidant is maqui powder.

9. A topical composition comprising, by weight:

0.2 to 0.4% capsaicin extract;

0.8 to 1.6% Cannabis sativa oil;

6 to 12% menthol;

4 to 8% skin permeator/anti-inflammatory;

2 to 4% analgesic;

2 to 4% analgesic/anti-inflammatory;

1.4 to 2.6% anesthetic; and,

1 to 2% antioxidant.

10. The composition of claim 9 where the skin permeator/anti-inflammatory is methyl sulfonyl methane.

11. The composition of claim 10 where the analgesic is Arnica montana.

12. The composition of claim 11 where the analgesic/anti-itch/counterirritant is camphor.

13. The composition of claim 12 where the analgesic/anti-inflammatory is Harpagophytim tincture.

14. The composition of claim 13 where the anesthetic is lidocaine.

15. The composition of claim 14 where the antioxidant is maqui powder.